Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease

Authors Franssen FME, Spruit MA, Wouters EFM

Published Date September 2011 Volume 2011:6 Pages 493—501

DOI http://dx.doi.org/10.2147/COPD.S24443

Published 26 September 2011

Frits ME Franssen1, Martijn A Spruit1, Emiel FM Wouters1,2
1Program Development Center, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands; 2Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

Background: Polypharmacy of respiratory medications is commonly observed in patients with chronic obstructive pulmonary disease (COPD). The aims of this study were to investigate determinants of polypharmacy and to study the consistency of actual respiratory drug use with current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in pulmonary rehabilitation candidates with COPD.
Methods: Data were extracted from the records of all patients with a diagnosis of COPD referred for pulmonary rehabilitation to CIRO+ between 2005 and 2009. Use of respiratory medications, self-reported COPD exacerbations, lung function, blood gases, exercise capacity, Medical Research Council (MRC) dyspnea grade, and St George’s Respiratory Questionnaire (SGRQ) were recorded as part of assessment of health status.
Results: In total, 1859 COPD patients of mean age (± standard deviation) 64.3 ± 9.7 years and with a forced expiratory volume in one second (FEV1) of 44.7% ± 18.2% were included. On average, patients used 3.5 ± 1.5 respiratory medications; this number increased with increasing GOLD stage, MRC score, and SGRQ scores. FEV1 (% predicted), SGRQ, and number of recent exacerbations were independent determinants of polypharmacy. Use of long-acting bronchodilators and inhaled corticosteroids was substantial and comparable in all GOLD stages. Use of corticosteroids was not restricted to patients with frequent exacerbations.
Conclusion: Polypharmacy of respiratory medications is common in COPD patients with persistent symptoms. In addition to severity of disease, health status is an independent predictor of polypharmacy. Actual drug use in COPD patients referred for pulmonary rehabilitation is partially inconsistent with current GOLD guidelines.

Keywords: chronic obstructive pulmonary disease, management, pharmacotherapy, polypharmacy, pulmonary rehabilitation, respiratory drug use

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes [Erratum]

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2015, 10:595-596

Published Date: 14 January 2015

Cognitive behavioral therapy for insomnia comorbid with COPD is feasible with preliminary evidence of positive sleep and fatigue effects

Kapella MC, Herdegen JJ, Perlis ML, Shaver JL, Larson JL, Law JA, Carley DW

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:625-635

Published Date: 24 November 2011

Spirometry for patients in hospital and one month after admission with an acute exacerbation of COPD

Rea H, Kenealy T, Adair J, Robinson E, Sheridan N

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:527-532

Published Date: 14 October 2011

Factors associated with good self-rated health and quality of life in subjects with self-reported COPD

Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:511-519

Published Date: 7 October 2011

Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients

Tzani P, Crisafulli E, Nicolini G, Aiello M, Chetta A, Clini E, Olivieri D

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:503-509

Published Date: 4 October 2011